collection
MENU ▼
Read by QxMD icon Read
search

Beavioral health

shared collection
10 papers 100 to 500 followers
By Christopher Cook Addiction professional. LPC, CADC, CRNP- student, Interventionist, project manager, owner, Director, eval/refer for SUDs/Eating D/o's, 60000 beds referral base
https://www.readbyqxmd.com/read/25706219/treatment-of-personality-disorder
#1
Anthony W Bateman, John Gunderson, Roger Mulder
The evidence base for the effective treatment of personality disorders is insufficient. Most of the existing evidence on personality disorder is for the treatment of borderline personality disorder, but even this is limited by the small sample sizes and short follow-up in clinical trials, the wide range of core outcome measures used by studies, and poor control of coexisting psychopathology. Psychological or psychosocial intervention is recommended as the primary treatment for borderline personality disorder and pharmacotherapy is only advised as an adjunctive treatment...
February 21, 2015: Lancet
https://www.readbyqxmd.com/read/21320390/evidence-based-pharmacotherapy-for-personality-disorders
#2
REVIEW
Luis H Ripoll, Joseph Triebwasser, Larry J Siever
Patients with personality disorders are prescribed psychotropic medications with greater frequency than almost any other diagnostic group. Prescribing practices in these populations are often based on anecdotal evidence rather than rigorous data. Although evidence-based psychotherapy remains an integral part of treatment, Axis II psychopathology is increasingly conceptualized according to neurobiological substrates that correspond to specific psychopharmacological strategies. We summarize the best available evidence regarding medication treatment of personality disordered patients and provide optimal strategies for evidence-based practice...
October 2011: International Journal of Neuropsychopharmacology
https://www.readbyqxmd.com/read/23982301/antidepressant-efficacy-of-ketamine-in-treatment-resistant-major-depression-a-two-site-randomized-controlled-trial
#3
RANDOMIZED CONTROLLED TRIAL
James W Murrough, Dan V Iosifescu, Lee C Chang, Rayan K Al Jurdi, Charles E Green, Andrew M Perez, Syed Iqbal, Sarah Pillemer, Alexandra Foulkes, Asim Shah, Dennis S Charney, Sanjay J Mathew
OBJECTIVE: Ketamine, a glutamate N-methyl-d-aspartate (NMDA) receptor antagonist, has shown rapid antidepressant effects, but small study groups and inadequate control conditions in prior studies have precluded a definitive conclusion. The authors evaluated the rapid antidepressant efficacy of ketamine in a large group of patients with treatment-resistant major depression. METHOD: This was a two-site, parallel-arm, randomized controlled trial of a single infusion of ketamine compared to an active placebo control condition, the anesthetic midazolam...
October 2013: American Journal of Psychiatry
https://www.readbyqxmd.com/read/27065833/bread-and-other-edible-agents-of-mental-disease
#4
REVIEW
Paola Bressan, Peter Kramer
Perhaps because gastroenterology, immunology, toxicology, and the nutrition and agricultural sciences are outside of their competence and responsibility, psychologists and psychiatrists typically fail to appreciate the impact that food can have on their patients' condition. Here we attempt to help correct this situation by reviewing, in non-technical, plain English, how cereal grains-the world's most abundant food source-can affect human behavior and mental health. We present the implications for the psychological sciences of the findings that, in all of us, bread (1) makes the gut more permeable and can thus encourage the migration of food particles to sites where they are not expected, prompting the immune system to attack both these particles and brain-relevant substances that resemble them, and (2) releases opioid-like compounds, capable of causing mental derangement if they make it to the brain...
2016: Frontiers in Human Neuroscience
https://www.readbyqxmd.com/read/22397264/the-use-of-a-food-supplementation-with-d-phenylalanine-l-glutamine-and-l-5-hydroxytriptophan-in-the-alleviation-of-alcohol-withdrawal-symptoms
#5
RANDOMIZED CONTROLLED TRIAL
Tomislav Jukić, Bojan Rojc, Darja Boben-Bardutzky, Mateja Hafner, Alojz Ihan
We described the use of a food supplementation with D-phenylalanine, L-glutamine and L-5-hydroxytriptophan in the alleviation of alcohol withdrawal symptoms in patients starting a detoxification therapy. Since abstinence from ethanol causes a hypodopaminergic and a hypoopioidergic environment in the reword system circuits, manifesting with withdrawal symptoms, food supplements that contains D-phenylalanine a peptidase inhibitor (of opioide inactivation) and L-amino-acids (for dopamine synthesis) were used to replenish a lack in neurotransmitters and alleviate the symptoms of alcohol withdrawal...
December 2011: Collegium Antropologicum
https://www.readbyqxmd.com/read/26277182/-the-endocannabinoid-system-role-in-the-pathogenesis-of-obesity-and-depression
#6
REVIEW
Anna Zdanowicz, Wieńczysław Kaźmierczak, Piotr Wierzbiński
Excessive consumption and obesity do not always have to be strictly pathological. The adjustment of food intake as well as the pleasure of eating are the results of the circulation of neurotransmitters, hormones and glucocorticoids which have an ability to regulate the activity of many receptors connected with G protein, including endocannabinoid receptors. The key role of endocannabinoids in pathogenesis of obesity is their overproduction by adipose cells. Endocannabinoids (eCBs) affect CB1 receptors and increase hunger, willingness to intake food, decrease peristalsis and delay stomach emptying...
July 2015: Polski Merkuriusz Lekarski: Organ Polskiego Towarzystwa Lekarskiego
https://www.readbyqxmd.com/read/26560523/mood-food-and-cognition-role-of-tryptophan-and-serotonin
#7
REVIEW
Barbara Strasser, Johanna M Gostner, Dietmar Fuchs
PURPOSE OF REVIEW: Food is not only necessary as a metabolic fuel for the body, it becomes more and more evident that there exists an association between food and brain functions like mood and cognition. Tryptophan represents a key element for brain functioning, because of its role as a precursor for production of neurotransmitter serotonin (5-hydroxytryptamine). In clinical conditions, which involve chronic immune system activation or under cytokine therapy, lower tryptophan levels because of high catabolism of tryptophan as indicated by the kynurenine to tryptophan ratio are common and often associate with depressive mood...
January 2016: Current Opinion in Clinical Nutrition and Metabolic Care
https://www.readbyqxmd.com/read/26806555/levo-tetrahydropalmatine-a-natural-mixed-dopamine-receptor-antagonist-inhibits-methamphetamine-self-administration-and-methamphetamine-induced-reinstatement
#8
Xiaokang Gong, Kai Yue, Baomiao Ma, Junqiao Xing, Yongping Gan, Daisong Wang, Guozhang Jin, Chaoying Li
Despite the high prevalence of methamphetamine (METH) use, no FDA-approved pharmacological treatment is currently available for individuals with a METH addiction. Levo-tetrahydropalmatine (l-THP) is an alkaloid substance derived from corydalis and stephania that has been used in traditional Asian medicine for its analgesic, sedative and hypnotic properties. Previous pharmacological studies of l-THP indicated that it not only binds to D1 and D2 receptors but also has a low affinity for D3 receptors and may function as an antagonist...
May 2016: Pharmacology, Biochemistry, and Behavior
https://www.readbyqxmd.com/read/24910934/treatment-of-major-depressive-disorder-using-botulinum-toxin-a-a-24-week-randomized-double-blind-placebo-controlled-study
#9
RANDOMIZED CONTROLLED TRIAL
Michelle Magid, Jason S Reichenberg, Poppy E Poth, Henry T Robertson, Amanda K LaViolette, Tillmann H C Kruger, M Axel Wollmer
OBJECTIVE: To determine whether a single treatment of botulinum toxin A in the forehead (glabellar) region can improve symptoms of depression in patients with major depressive disorder (MDD), as defined by DSM-IV criteria. METHOD: Thirty participants were randomly assigned to receive either placebo or botulinum toxin A (BTA; onabotulinumtoxinA) injections in the forehead. Female participants received 29 units; male participants received 39 units. At week 12, the groups were crossed over...
August 2014: Journal of Clinical Psychiatry
https://www.readbyqxmd.com/read/23421417/flibanserin-treatment-increases-appetitive-sexual-motivation-in-the-female-rat
#10
Hélène Gelez, Jonathan Greggain-Mohr, James G Pfaus, Kelly A Allers, François Giuliano
INTRODUCTION: Flibanserin is a mixed 5-HT1A agonist/5-HT2A antagonist that has been developed for the treatment of hypoactive sexual desire disorder in women. AIM: To assess the acute and chronic dose-response effects of flibanserin on measures of sexual desire and copulation in ovariectomized rats primed with estradiol benzoate (EB) alone or in combination with progesterone (P). METHODS: In Experiment 1, sexually experienced ovariectomized (OVX) rats at one testing site were rendered fully sexually receptive with EB + P priming and tested weekly with a sexually active male in bi-level pacing chambers following daily flibanserin treatment for 28 days...
May 2013: Journal of Sexual Medicine
1
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"